65,437 trials
COVID-19
Primary: Prevention of COVID-19 Complications or Death: During the 30-day Treatment Period, Time to First Occurrence of New/Worsened Organ Dysfunction During Index…
Non-Small Cell Lung Cancer · Metastatic Non-small Cell Lung Cancer · Squamous Cell Carcinoma
Primary: Rate of Dose Limiting Toxicity (DLT) — 17 % participants w severe toxicity
Posttraumatic Stress Disorder (PTSD)
Primary: Primary Outcome: Clinician Administered PTSD Scale (CAPS) — 26.44; 15.96 units on a scale
Migraine
Primary: Change in Migraine Interictal Burden Scale (MIBS-4) Scores From Baseline to Weeks 4, 8, and 12. — -1.05; -0.37; -1.71; -0.63 score on a scale
Solid Tumor
Primary: Area Under the Concentration-Time Curve Zero Time Extrapolated to Infinite Time (AUC0-∞) — 5033.5; 5595.9 ng*h/mL
Cardiac Amyloidosis
Primary: Mean Left Ventricular Myocardial F-18 Florbetapir SUVmean — 3.2; 1.7; 5.0 ratio
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) of Carfilzomib in Bortezomib naïve and Bortezomib-exposed Relapsed WM — 85.7 percentage of participants
Familial Chylomicronemia Syndrome
Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — 17.6; -76.5 percent change — p=< 0.0001
Hypertriglyceridemia
Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — -0.9; -71.2 percent change — p=<0.0001
Carcinoma · Non-Squamous Non-Small-Cell Lung Cancer
Primary: Tumor Response Rate (RR) — 0; 0; 0; 0 percentage of participants — p==0.384
COVID-19
Primary: Time to Respiratory Viral Clearance — 3.39; 3.44 Days
Postpartum Hemorrhage
Primary: Efficacy: Rate of Participants With Cessation of Uterine Hemorrhaging — 100 Participants
Pain
Primary: Change From Baseline in Pain on Movement (POM) on Day 5 of Treatment as Assessed by a 100 Millimeter (mm) Visual Analogue Scale (VAS) — -42.36; -43.47 mm — p=0.5950
Psoriasis
Primary: • The Percent Change in PASI (Psoriasis Area and Severity Index) Score From Baseline — -38.1; -48.2; -50.7; -25.0 percentage change from baseline — p=0.066
Soft Tissue to Bone Fixation
Primary: Number of Participants With Clinical Success of the Study Devices in the Shoulder Over a Time Period of 6 Months After Intervention — 185; 6; 38; 3 Participants